Join our experts as they discuss the role of probiotics in Clostridioides difficile infection (CDI), review the differences between traditional fecal microbiota transplant and emerging live biotherapeutic products (LBP), and summarize the expanded indications and safety profiles of LBP pipeline drugs.
The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.